GT Biopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	0	0	0	0	0	0	0	0	0.03	0.06
Revenue Growth (YoY)	-	-	-	-	-	-	-	-	-55.74%	-
Cost of Revenue	0	0	0	0	0	0	0	0	0	0.06
Gross Profit	0	0	0	0	0	0	0	0	0.03	0
Selling, General & Admin	7.11	12.45	47.92	6.28	9.79	12.49	134.5	8.4	7.95	2.4
Research & Development	6.47	8.81	9.59	0.49	1.67	9.07	1.07	0.98	1	0
Other Operating Expenses	0	0	0	0	4.6	228.52	0	0	0	0
Operating Expenses	13.58	21.26	57.52	6.76	16.06	250.07	135.57	9.37	8.95	2.4
Operating Income	-13.58	-21.26	-57.52	-6.76	-16.06	-250.07	-135.57	-9.37	-8.93	-2.4
Interest Expense / Income	0.21	0.01	0.72	3	2.13	9.12	8.6	6.56	17.04	5.15
Other Expense / Income	-6.19	-0.38	-0.22	18.53	20.46	-	-	-25.7	-4.54	15.95
Pretax Income	-7.6	-20.88	-58.01	-28.3	-38.65	-259.19	-144.17	9.77	-21.43	-23.49
Net Income	-7.6	-20.88	-58.01	-28.3	-38.65	-259.19	-144.17	9.77	-21.43	-23.49
Shares Outstanding (Basic)	1	1	1	0	0	0	0	0	0	0
Shares Outstanding (Diluted)	1	1	1	0	0	0	0	0	0	0
Shares Change	26.87%	13.19%	542.06%	29.59%	14.50%	199.60%	20450.00%	-96.59%	2.87%	-
EPS (Basic)	-5.64	-19.66	-61.80	-193.50	-0.30	-2631.60	-4386.00	61154.10	-4569.60	-5145.90
EPS (Diluted)	-5.64	-19.66	-61.80	-193.50	-0.30	-2631.60	-4386.00	61154.10	-4569.60	-5145.90
Free Cash Flow	-8.85	-15.22	-15.61	-7.26	-3.46	-10.71	-5.43	-1.93	-4.66	-
Free Cash Flow Per Share	-6.57	-14.32	-16.63	-49.68	-30.66	-108.75	-165.27	-12083.27	-992.08	-
Gross Margin	-	-	-	-	-	-	-	-	100.00%	6.56%
Operating Margin	-	-	-	-	-	-	-	-	-33062.96%	-3927.87%
Profit Margin	-	-	-	-	-	-	-	-	-79374.07%	-38506.56%
Free Cash Flow Margin	-	-	-	-	-	-	-	-	-17251.85%	-
EBITDA	-7.38	-20.88	-57.3	-25.29	-36.52	-250.06	-135.57	16.32	-4.39	-
EBITDA Margin	-	-	-	-	-	-	-	-	-16259.26%	-
Depreciation & Amortization	0	0	0	0	0	0.01	0	0	0	-
EBIT	-7.38	-20.88	-57.3	-25.29	-36.52	-250.07	-135.57	16.32	-4.39	-18.34
EBIT Margin	-	-	-	-	-	-	-	-	-16266.67%	-30070.49%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).